Medication following bariatric surgery for type 2 diabetes mellitus

  • Research type

    Research Study

  • Full title

    Medication following bariatric surgery for type 2 diabetes mellitus

  • IRAS ID

    271669

  • Contact name

    Alex Miras

  • Contact email

    a.miras@nhs.net

  • Sponsor organisation

    Imperial College London

  • Clinicaltrials.gov Identifier

    NCT04432025

  • Duration of Study in the UK

    6 years, 0 months, 1 days

  • Research summary

    The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

  • REC name

    London - Fulham Research Ethics Committee

  • REC reference

    20/LO/1156

  • Date of REC Opinion

    8 Dec 2020

  • REC opinion

    Further Information Favourable Opinion